Kornimate/medical-research-clean huggingface dataset:
exercise oscillatory breathing and sildenafil in heart failure

Conditions: Heart Failure

Summary: exercise oscillatory breathing (eob) is a ventilatory abnormality that occurs in approximately 20% of heart failure (hf) patients and carries a very unfavourable prognosis. pathophysiology seems quite complex and putative mechanisms include increased pulmonary capillary pressure and pulmonary vasoconstriction, circulatory blood-flow fluctuations in the pulmonary arterial system and instability of ventilatory control. inhibition of the phosphodiesterase 5 (pde5) isoenzyme favourably regulates pulmonary vascular tone and permeability through over signaling of the endothelial nitric oxide pathway. the investigators tested the hypothesis that sildenafil would reverse the eob pattern in patients with hf and pulmonary hypertension.


Eligibility criteria:
inclusion criteria: * consent to participate in the study after detailed information about benefits and risks * negative exercise stress test prior to study initiation * forced expiratory volume in 1 sec/forced vital capacity ratio \>70%; * lvef \< 45%. exclusion criteria: * inability to complete a maximal exercise test * resting systolic blood pressure \> 140 or \<110 mmhg * therapy with nitrate preparations * history of sildenafil intolerance * significant lung or valvular diseases * neuromuscular disorders or peripheral vascular disease

Keywords: pde5-inhibition exercise ventilation heart failure sildenafil pulmonary hemodynamics
behavioral activation for opioid use disorder

Conditions: Opioid Use Disorder

Summary: the overall purpose of this pilot study is to evaluate the feasibility and acceptability of values-based behavioral activation (ba) as an adjunct intervention for patients receiving medications for opioid use disorder (oud) in primary care. researcher will evaluate the following aims: 1) examine the feasibility of ba for oud in primary care, 2) examine whether the ba intervention and study requirements are acceptable to participants, and 3) determine the psychometric properties of the outcome measures in people with oud. participants will complete 4-6 brief counseling sessions over the course of 12 weeks. during the first session, participants will discuss values and recovery outcomes important to them. next, they will set 2-3 personal goals to work on before the next ba session. at the follow-up sessions, participants will update the counselor on progress made or challenges experienced. personal values will be reviewed and participant goals updated. study measures (surveys and urine drug tests) will be completed at the start, partway through, and at the end of the intervention.


Eligibility criteria:
inclusion criteria: * at least 18 years of age. * diagnosis of opioid use disorder. * have an active prescription for buprenorphine-naloxone (suboxone) for at least one month. * patient at broadway family medicine (bfm) exclusion criteria: * concurrent individual psychotherapy with a psychologist or counselor at least monthly * active suicidal ideation (intention, plan, or attempt in the past 30 days, as determined by chart review) * dementia, developmental disabilities, or cognitive functioning that is too low to participate in therapy, as determined by chart review

Keywords: opioid use disorder behavioral activation primary care buprenorphine
lenalidomide in treating patients with advanced or unresectable kidney cancer

Conditions: Kidney Cancer

Summary: rationale: biological therapy such as lenalidomide use different ways to stimulate the immune system and stop tumor cells from growing. it may also stop the growth of tumor cells by stopping blood flow to the tumor. purpose: this phase ii trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney cancer.

objectives: primary * determine the best response in patients with advanced or unresectable renal cell cancer treated with lenalidomide (cc-5013). * determine the time to disease progression in patients treated with this drug. secondary * determine the safety of this drug in these patients. outline: this is an open-label study. patients receive oral lenalidomide (cc-5013) once daily on days 1-21. courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. patients are followed at 30 days and then every 3 months thereafter. projected accrual: a total of 14-25 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed renal cell carcinoma (rcc) * advanced or unresectable disease * at least 1 measurable lesion * no active brain metastases * prior brain metastases allowed provided patient has been treated with radiotherapy or surgery and remains asymptomatic for ≥ 6 months patient characteristics: age * 18 and over performance status * karnofsky 70-100% life expectancy * not specified hematopoietic * absolute neutrophil count ≥ 1,500/mm\^3 * platelet count ≥ 100,000/mm\^3 hepatic * bilirubin ≤ 1.5 mg/dl * ast and alt ≤ 2 times upper limit of normal (uln) (5 times uln if liver metastases are present) * no hepatitis a, b, or c infection renal * creatinine ≤ 2.0 mg/dl other * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * hiv negative * no known hypersensitivity to thalidomide * no other serious medical condition, laboratory abnormality, or psychiatric illness that would preclude giving informed consent * no other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or breast, localized prostate cancer, or superficial bladder cancer prior concurrent therapy: biologic therapy * no more than 1 prior systemic immunotherapy regimen for rcc * no prior lenalidomide (cc-5013) * no prior or concurrent thalidomide chemotherapy * no more than 1 prior systemic chemotherapy regimen for rcc endocrine therapy * no more than 1 prior systemic hormonal therapy regimen for rcc radiotherapy * see disease characteristics * no concurrent radiotherapy surgery * see disease characteristics * at least 4 weeks since prior surgery and recovered other * no more than 1 other prior systemic therapy regimen for rcc * no other concurrent anticancer therapies * no other concurrent investigational agents

Keywords: recurrent renal cell cancer stage iii renal cell cancer stage iv renal cell cancer
early mobilization with and without chest physiotherapy in chronic bronchitis patients.

Conditions: Chronic Bronchitis

Summary: it will be a randomized control trial study in which data are collected from hospital. a sample of 26 patients will divided into two group. one group of 13 patients will receive early mobilization and other group of 13 patients will receive early mobilization and chest physiotherapy only. all subject will receive 30 minute two session per day till two weeks. outcome will be measured with mrc dyspnea scale and pulmonary function test with spirometry to measure fev1 and fev1/fvc and quality of life will be checked by using st. george's respiratory questionnaire. data will be analyzed by using spss version 21.

it will be a randomized control trial study in which data are collected from jinnah hospital lahore. a sample of 26 patients will be included and divided into two group. one group of 13 patients will receive early mobilization with chest physiotherapy and other group of 13 patients will receive early mobilization only. all subject will receive 30 minute two session per day till two weeks. outcome will be measured with mrc dyspnea scale and pulmonary function test with spirometry to measure fev1 and fev1/fvc and quality of life will be checked by using st. george's respiratory questionnaire. data will be analyzed by using spss version 21.

Eligibility criteria:
inclusion criteria: * both gender of age 45-70 years * patient diagnosed with chronic bronchitis (admitted patients) * taking bronchodilators exclusion criteria: * • patient having any other condition cardiovascular, diabetes mellitus and neurological conditions * patient history of radiotherapy * unconscious icu patients * patient received any pre-admitted physiotherapy protocol

Keywords: early mobilization, chest physiotherap, chronic bronchitis
intercellular adhesion molecule-1 and tnf-α in patients with covid-19

Conditions: COVID-19; Cytokine Storm

Summary: this study aimed to assess the cytokine profile in covid 19 patients and its relation with disease progression \& severity using covid reporting and data system (corads) score.

study participants this was a prospective case control study done from february to december 2021, 50 covid19 patients and 50 control participants after taking their written consents were recruited from the emergency department and outpatient clinic to the medical microbiology and immunology department and infection control unit in benha university hospital, benha, egypt. blood samples were taken at admission from each patient and repeated during the convalescence period for severe pneumonic cases. serum c-reaction protein (crp), d-dimer, lipids and glucose were determined by conventional laboratory methods. blood samples of the control group were also collected and tested. the obtained blood samples were placed in tubes containing edta and blank tubes then immediately centrifuged at 1500g and stored at -80°c. enzyme-linked immunosorbent assay quantitative detection for tumor necrosis factor alfa (tnf-α) \& intercellular adhesion molecule1 (icam-1) was performed using elisa kits ( bio reader by thermo fisher scientific waltham, ma usa) according to the manufacture instructions. statistical analysis data were analysed using spss software, version 25.0 (ibm, armonk, ny, usa) for windows. quantitative data were tested for normality using kolomograph test assuming normality at p\>0.05. they were proved to be non parametric, so they were presented as median and inter-quartile range (iqr), and analyzed by man whitney u test and kruskal wallis (kw) test for independent groups. p ≤0.05 was considered significant p value \>0.05 insignificant p≤0.05 significant p\<0.001 highly significant

Eligibility criteria:
inclusion criteria:all patients confirmed by rt-pcr, as positive for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) who visited the emergency room and the outpatient clinic in the study period. the control group included 50 healthy volunteers. - exclusion criteria: -

Keywords: covid19 icam cytokines tnf
spi-1005 treatment in moderate covid-19 patients

Conditions: Covid19; Corona Virus Infection; Coronavirus; Coronavirus Infection

Summary: the study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (rct) of spi-1005 in adult subjects with positive pcr test for novel sars-cov-2 (ncov2) and moderate symptoms of covid-19 disease.


Eligibility criteria:
inclusion criteria: * adults ≥18 years of age * positive ncov2 pcr test by nasopharyngeal, oral, saliva, or respiratory sample * clinical signs, symptoms, and respiratory status consistent with moderate covid-19 * score of 3-4 on the who ordinal scale * onset of moderate covid-19 symptoms ≤3 days of study enrollment * subject is in-patient at time of randomization to study treatment * subject or legally authorized representative is willing and able to provide informed consent, and agrees for subject to comply with planned study procedures including reproductive requirements. exclusion criteria: * female patients who are pregnant or breastfeeding. * participation in another interventional investigational drug or device study concurrently or within 30 days prior to study consent. * patients with impaired hepatic or renal function. * subject has any other illness or condition that, in the opinion of the investigator, would prohibit the subject from participating.

Keywords: ebselen spi-1005 covid-19 covid sars-cov-2 mpro main protease plpro papain-like protease
management of type-2 diabetic patients treated with insulin during the ramadan

Conditions: Diabetes Type 2; Treatment During Ramadan

Summary: fasting during the ramadan is one of the five pillars of islam and is a mandatory duty for all healthy adult muslims. fasting is considered safe in young healthy subjects but it can induce harmful effects and complications in patients with diabetes. several studies have demonstrated that patients with type 2 diabetes are prone to hypo and hyper glycemia during fasting. when treating diabetic patients with a treatment guideline the rate of these complications can be reduced. little data is available on patients with type 2 diabetes treated with insulin. the investigators therefore propose to assess the effect of a protocol containing detemir (levemir) and a premix of insulin aspart (novomix70) on glucose control in patients with type 2 diabetes during the ramadan and to compare this regimen to the standard care patients receive during this period. the investigators assume that patients receiving the intervention will have better glucose control during the ramadan compared to patients receiving the standard care. as approximately 45 million muslims suffer from type 2 diabetes and most of them fast during the ramadan the results of this intervention may be significant and may improve the care of these patients allowing muslims to respect their religious obligations without compromising their health.


Eligibility criteria:
inclusion criteria: all of these criteria should be present. 1. patients with a diagnosis of type 2 diabetes treated with insulin (premix preparations or basal and rapid acting insulin) with or without metformin and/or a sulfonylurea drug for at least three months 2. hba1c in the past three months ≤ 10% 3. being capable, and willing, to perform self blood glucose monitoring and use a patient diary as required 4. age \> 18 years exclusion criteria: any of the following: 1. patients with a diagnosis of type 1 diabetes 2. hypoglycemia unawareness 3. hypersensitivity to levemir 4. hypersensitivity to novomix70 5. creatinine \> 2.5 mg/l 6. ast and or alt \> 1.5 times the upper limit 7. pregnancy 8. mental incapacity, unwillingness or language barrier precluding adequate understanding of the study protocol or cooperation

Keywords: diabetes type 2 fasting ramadan insulin analogues
nas-nrc twin registry

Conditions: Cardiovascular Diseases; Heart Diseases; Coronary Disease; Myocardial Ischemia; Obesity

Summary: to continue a registry of world war ii veteran twins maintained by the national academy of sciences-national research council (nas-nrc).

background: the registry of world war ii veteran twins came into existence in the late 1960's through a search and link effort of state vital statistics records and veterans administration files through the medical follow-up agency of nas-nrc. since that time, the registry has served as a data resource for investigators in a variety of scientific fields who want to study genetic and environmental aspects of various human characteristics. because of the size and geographic coverage throughout the united states, the registry offers a method of recruiting sizeable numbers of twins for study even under geographic restrictions. of special value to medical researchers is the built-in medical follow-up for morbidity and mortality through veterans administration insurance and benefits records. this allows researchers to gather baseline data which may be related prospectively to morbidity and mortality events. the nhlbi has made extensive use of the world war ii veteran twin registry beginning in 1969, when the nhlbi twin study was initiated. at that time, nhlbi used the world war ii veteran twin registry to recruit a group of 514 pairs of twins in five geographic areas to participate in a study which included a battery of questionnaires and a physical examination. since that time, a second examination and third examination of the cohort have been completed and the registry has been used to maintain contact with the twins and provide surveillance for morbidity and mortality events of the participants in the study. design narrative: maintenance of the existing registry continued as addresses of all members were updated annually as well as morbidity and mortality data through surveillance of veterans administration insurance and death benefit records or through the national death index. all morbid events and deaths were coded by icd codes. support activities were provided for the nhlbi twin study including providing death certificates for events occurring among the 1,028 twins participating in the study and mailed questionnaire follow-up. although contract support ended in september, 1988, analyses of the survey and mortality data are continuing.

Eligibility criteria:
no eligibility criteria
early basal insulin administration in adult diabetic ketoacidosis management

Conditions: Diabetic Ketoacidosis; Type 1 Diabetes; Type 2 Diabetes

Summary: early basal insulin administration in adult diabetic ketoacidosis management

the transition from iv insulin infusion (ivii) to subcutaneous long-acting insulin injections in diabetic ketoacidosis (dka) management frequently results in rebound hyperglycemia, particularly if there are high insulin requirements that can adversely affect the dka recovery, increase length of stay (los), morbidity, and mortality. investigators propose a prospective, open-label, intervention, non-randomized, controlled study to test the hypothesis that an insulin glargine dose of 0.4 units/kg early administered (within four hours) of ivii initiation in dka management in adult would be effective and safe in shortening the time to anion gap closure comparing to the standard practice.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * meet dka definition (bg ≥ 250 mg/dl, anion gap \> 12 meq/l, and positive ketones in serum or urine) * having the capacity to sign informed consent exclusion criteria: * iv insulin infusion was initiated for more than 4 hours. * persistent hypotension (sbp\<80 mmhg despite receiving 1000cc normal saline). * require vasopressor * acute coronary syndrome * pregnant * end-stage renal disease * unwilling to consent to participate in the trial * currently under police custody * transferred from another hospital * require emergent surgery
the safety and efficacy of basiliximab as maintenance therapy in subjects with stable, noninfectious uveitis

Conditions: Non-infectious Uveitis

Summary: the objective of this trial is to assess if treatment with basiliximab allows subjects to taper off other immunosuppressive drug regimens without causing an increase in their uveitis.


Eligibility criteria:
inclusion criteria: * diagnosis of noninfectious intermediate, posterior or panuveitis of at least 3 months duration * treatment with greater than or equal to 20 mg/day of prednisone at baseline or immunosuppressive drug score of greater than or equal to 5 at baseline * bcva by etdrs protocol better than or equal to 20/200 * intraocular pressure of 24 mmhg or less * anterior chamber cells and vitreous haze of less than or equal to 1 * male or females, aged 12 or greater, body weight of 40 kg or greater exclusion criteria: * prior treatment with retisert * primary diagnosis of anterior uveitis, uveitis of infectious etiology or behcet's disease * pregnancy or breast-feeding * increase in systemic immunosuppressive treatment regimen within 6 weeks before baseline

Keywords: non-infectious uveitis
safety and efficacy of intravitreal ranibizumab as a preoperative adjunct treatment before vitrectomy surgery in proliferative diabetic retinopathy (pdr) compared to vitrectomy alone

Conditions: Diabetic Retinopathy

Summary: this study investigates the hypothesis that ranibizumab injection given into the eye is a safe, efficacious and helping treatment option applied before surgical intervention of the proliferative diabetic retinal eye disorder.

this is a randomized, double blinded , controlled, two-center study assessing the feasibility, efficacy and safety of intravitreal ranibizumab injection applied as a preoperative adjunct treatment before vitrectomy surgery in severe proliferative diabetic retinopathy (pdr). comparator arm consists of patients receiving standard vitrectomy alone with sham intravitreal injection preoperatively.

Eligibility criteria:
inclusion criteria: * male or female 18 or older who have signed an informed consent * type i or ii diabetes mellitus and severe proliferative retinopathy with tractional retinal detachment, tractional-rhegmatogenous retinal detachment, tractional detachment complicated with vitreous haemorrhage or active severe proliferative retinopathy not responding to previous panretinal laser photocoagulation * study eye bcva must have at least light perception and must not exceed 70 letters using etdrs at testing distance 4 meters * study eye vision decrease must be resulted from severe pdr exclusion criteria: * active ocular inflammation or infection * history of uveitis * uncontrolled glaucoma * high myopia * any concurrent intraocular condition in the study eye that in the opinion of the investigator could confound the study results * former treatment with anti-angiogenic drugs within 30 days preceding day 1 in the study eye * history of vitrectomy within 60 days preceding day 1 in the study eye * history of intraocular surgery within 30 days preceding day 1 in the study eye * untreated diabetes mellitus * severe hypertension (systolic pressure higher than 160mmhg) * current use of systemic medications known to be toxic to the retina * history of thromboembolic events (incl mi and stroke) within 5 years * major surgery within previous 3 months or planned within the next 28 days * known coagulation abnormalities or current use of anticoagulative medications other than aspirins * known hypersensitivity to ranibizumab or any component of it * women of childbearing potential unless 2 methods of birth control applied * pregnant or lactating women

Keywords: severe proliferative diabetic retinopathy